Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Equity Average (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Equity Average for 15 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average changed 0.48% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Sep 2025, changed 0.48%, and an annual FY2024 reading of $4.2 million, down 81.34% over the prior year.
  • Equity Average was $3.2 million for Q3 2025 at Alaunos Therapeutics, up from $2.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $114.8 million in Q1 2021 and bottomed at $1.6 million in Q1 2025.
  • Average Equity Average over 5 years is $33.3 million, with a median of $25.6 million recorded in 2023.
  • The sharpest move saw Equity Average tumbled 83.68% in 2024, then fell 0.48% in 2025.
  • Year by year, Equity Average stood at $63.4 million in 2021, then tumbled by 44.25% to $35.3 million in 2022, then tumbled by 71.41% to $10.1 million in 2023, then crashed by 76.31% to $2.4 million in 2024, then soared by 35.03% to $3.2 million in 2025.
  • Business Quant data shows Equity Average for TCRT at $3.2 million in Q3 2025, $2.4 million in Q2 2025, and $1.6 million in Q1 2025.